Deutsche Bank Remains a Buy on Qiagen (QGEN)

Deutsche Bank analyst Falko Friedrichs maintained a Buy rating on Qiagen (QGEN – Research Report) today. The company’s shares opened today at $41.56.

Friedrichs covers the Healthcare sector, focusing on stocks such as Qiagen, Siemens Healthineers AG, and Demant. According to TipRanks, Friedrichs has an average return of -2.3% and a 40.00% success rate on recommended stocks.

In addition to Deutsche Bank, Qiagen also received a Buy from Bank of America Securities’s Michael Ryskin in a report issued today. However, on the same day, Stifel Nicolaus maintained a Hold rating on Qiagen (NYSE: QGEN).

The company has a one-year high of $47.74 and a one-year low of $34.77. Currently, Qiagen has an average volume of 1.03M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Qiagen (QGEN) Company Description:

QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.